Navigation Links
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
Date:12/10/2007

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL), today reported phase 1 data from an ongoing phase 1 trial of XL019 in patients with myelofibrosis, a myeloproliferative disorder (MPD). XL019 is an investigational small molecule that selectively inhibits the tyrosine kinase JAK2, one of four JAK family members activated in response to cytokines and hematopoietic growth factors. JAK2 is inappropriately activated in the majority of MPD patients and is deregulated in a number of solid tumors, including certain subtypes of lymphoma. Dr. Srdan Verstovsek from the M. D. Anderson Cancer Center, Houston, TX today presented data from an ongoing phase 1 study in an oral presentation session (Abstract #553) at the American Society of Hematology 49th Annual Meeting and Exposition, which is taking place in Atlanta, December 8th-11th.

"We are very encouraged by the results from this ongoing trial that show rapid decrease in spleen size and relief of disease-related symptoms at low doses of XL019. XL019 is a highly selective inhibitor of JAK2 that may have the potential to provide important benefit for patients with myeloproliferative disorders and other diseases driven by JAK2," said Michael Morrissey, Ph.D., president of research and development at Exelixis. "We believe that JAK2 is a critical target in myeloproliferative disorders, and effective inhibition of JAK2 may directly translate into clinical benefit. The strong linkage of JAK2 to MPDs provides a potentially quick route to market, with potential for additional opportunities in larger commercial indications. We are planning to initiate pivotal trials of XL019 in myelofibrosis patients in 2008."

Trial Design

The phase 1 dose escalation study of XL019 is ongoing in subjects with primary myelofibrosis (MF) and post-polycythemia vera/essential thrombocythemia MF. To date nine patients have been enrolled. The primary objective of this study is to determine the safety and tol
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Calif. , May 26, 2015  Accuray Incorporated ... team is scheduled to present at the Jefferies 2015 ... on Wednesday, June 3, 2015 at 2:30pm ET.   ... be available on the Investor Relations page of the ... of the presentation will begin approximately one hour after ...
(Date:5/26/2015)... Pa. , May 26, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... that Bob Radie , president and chief ... conferences in June. He will provide an update ... (ketorolac tromethamine) Nasal Spray, approved product ...
(Date:5/22/2015)... - The Taskforce representing Canada,s living ... work that the Minister and Health Canada have put into ... the needs of the thalidomide survivors, and more than 70% ... free, with annual adjustments for inflation. Certain of ... $100,000 based on the severity of their disability, tax free, ...
Breaking Medicine Technology:Egalet to Present at Upcoming Conferences in June 2Egalet to Present at Upcoming Conferences in June 3
(Date:5/26/2015)... (PRWEB) May 26, 2015 Based on ... AnyTranscription has undertaken a comprehensive upgrade of its purchasing ... user experience. To thank users for their feedback and ... five minute trial transcription service promotion. , ... May 26 to June 9 this year. During this ...
(Date:5/26/2015)... Adenna, Inc ., worldwide supplier of ... announce the launch of Enov8 (pronounced “innovate”), ... polyethylene (PE) and approved by the U.S. FDA for ... , The Enov8 glove might look like the PE ... but our proprietary formula and production technology brings to ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Learning ZoneXpress ... line, Nutrition Education Cards . These cards have ... engaging photography and simple, easy-to-read text, these new educational ... . They offer practical nutrition tips and suggestions to ... titles available are: , + MyPlate: Eat for a ...
(Date:5/26/2015)... Many sexy cocktail dresses inspired by celebrities ... recently. Now, TheCelebrityDresses.com is offering great discounts on ... off. The company aims to help ladies from ... dollars on valuable, trendy formal outfits. , TheCelebrityDresses.com ... special occasion dresses. Their dresses are popular among ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 U.S. Food ... in the United States are extensive and can be ... firm that helps medical device companies comply with FDA ... medical device companies navigate FDA requirements. , 1. ... the United States can be a lengthy process depending ...
Breaking Medicine News(10 mins):Health News:Enjoy AnyTranscription’s First-class Audio/Video Transcription Service for Just $0.01 2Health News:Enjoy AnyTranscription’s First-class Audio/Video Transcription Service for Just $0.01 3Health News:Enov8® Exam Glove by Adenna® Approved by U.S. FDA 2Health News:Learning ZoneXpress Introduces New Educational Resource for WIC, SNAP-Ed, and EFNEP 2Health News:Cocktail Dresses Inspired by Celebrities on Sale at TheCelebrityDresses.com 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 3Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 4
... Orleans, La. -March 26, 2009 Nearly 90 percent of ... are caused by a blockage of blood vessels supplying ... published in Catheterization and Cardiovascular Interventions , the ... Interventions (SCAI), provides solid evidence of the effectiveness of ...
... Leading Neurological Testing Company Offers Top-Tier Developers And ... Market GamesBERKELEY, Calif., March 26 As the ... double-digit growth, the competition to create the next ... www.neurofocus.com ), the company that leads the global ...
... to Address Rare GI Cancers and Colorectal Screening ... American College of Gastroenterology and its more than ... Senator Kay Bailey Hutchinson today for the introduction ... Early detection, Research and Treatment) Act" and their ...
... imaging, researchers say , , THURSDAY, March 26 (HealthDay News) ... can better detect molecular changes inside the body that ... University chemists. , MRI uses hydrogen atoms in water ... radio waves, but the process requires a huge number ...
... 26 Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and ... Roche has completed its acquisition of Genentech pursuant to ... member of the Roche Group. Roche had announced earlier ... offer, which expired on Wednesday, March 25. In connection ...
... Smith to carry message that good lifestyle choices help prevent ... Smith believes the best offense is a good defense - ... learned to be vigilant about diabetes in his own family. ... motivates me quite a bit. I think about all the ...
Cached Medicine News:Health News:Individualized stroke treatment available for patients, though underutilized 2Health News:NeuroFocus Launches NGame; New Suite of Neuromarketing Products and Services for the Videogame Industry Elite 2Health News:NeuroFocus Launches NGame; New Suite of Neuromarketing Products and Services for the Videogame Industry Elite 3Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 2Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 3Health News:Roche Completes Acquisition of Genentech 2Health News:Blue Cross and Blue Shield of Illinois Teams with Chicago Bears Coach Lovie Smith in Diabetes Awareness Drive 2Health News:Blue Cross and Blue Shield of Illinois Teams with Chicago Bears Coach Lovie Smith in Diabetes Awareness Drive 3Health News:Blue Cross and Blue Shield of Illinois Teams with Chicago Bears Coach Lovie Smith in Diabetes Awareness Drive 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: